Home
About
Overview
Sharing Data
ORCID
Help
History (9)
Untying the gordion knot of targeting MET in cancer.
Mind-mapping for lung cancer: towards a personalized therapeutics approach.
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions.
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
See All 9 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon? J Carcinog. 2013; 12:7.
View in:
PubMed
authors with profiles
Ravi Salgia